...
首页> 外文期刊>Infection and immunity >Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and from an Escherichia coli recombinant strain and efficacy against lethal plague challenge.
【24h】

Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and from an Escherichia coli recombinant strain and efficacy against lethal plague challenge.

机译:从鼠疫耶尔森氏菌CO92和大肠杆菌重组菌株中纯化级分1荚膜抗原(F1),并具有对抗致命鼠疫攻击的功效。

获取原文

摘要

As a first step in formulating an improved plague vaccine, we developed a simple purification strategy that produced high yields of pure cell-associated and culture supernatant-derived fraction 1 capsular antigen (F1) from both avirulent Yersinia pestis C092 (Pgm- Lcr-) and an Escherichia coli F1-producing recombinant strain. Cell-associated F1 was partially purified by sequential ammonium sulfate precipitations of a sodium chloride extract of acetone-dried bacteria harvested from broth cultures. Cell-free F1 was precipitated directly from culture supernatants with a single application of 30% ammonium sulfate. By exploiting the aggregative property of F1, large quantities of purified high-molecular-weight F1 species from both cell extracts and supernatants were isolated in the void volume of a preparative gel filtration column. Highly purified, endotoxin-free F1, combined with two different adjuvants, induced very high F1 titers in mice and protected them against either subcutaneous (70 to 100% survival) or aerosol (65 to 84% survival) challenge with virulent organisms. This protection was independent of the source of the antigen and the adjuvant used. F1-induced protection against both subcutaneous and aerosol challenge was also significantly better than that conferred by immunization with the licensed killed whole-cell vaccine. Our results indicate that F1 antigen represents a major protective component of previously studied crude capsule preparations, and immunity to F1 antigen provides a primary means for the host to overcome plague infection by either the subcutaneous or respiratory route.
机译:作为配制改良鼠疫疫苗的第一步,我们开发了一种简单的纯化策略,可从两种无毒力耶尔森氏菌C092(Pgm-Lcr-)产生高产量的纯细胞相关和培养上清液衍生的级分1荚膜抗原(F1)。和产生大肠杆菌F1的重组菌株。通过从发酵液培养物中收获的丙酮干燥细菌的氯化钠提取液的连续硫酸铵沉淀,部分纯化与细胞相关的F1。一次施用30%硫酸铵即可直接从培养上清液中沉淀出无细胞的F1。通过利用F1的聚集特性,从细胞提取物和上清液中分离出大量纯化的高分子量F1物种,位于制备性凝胶过滤柱的空白体积中。高度纯化的无内毒素的F1与两种不同的佐剂结合,在小鼠中诱导了很高的F1效价,并保护它们免受有毒生物对皮下(存活率70%至100%)或气溶胶(存活率65%至84%)的攻击。这种保护独立于抗原的来源和所用的佐剂。 F1诱导的针对皮下和气溶胶攻击的保护也明显优于使用许可的杀死全细胞疫苗免疫所提供的保护。我们的结果表明F1抗原代表了以前研究的粗胶囊制剂的主要保护成分,对F1抗原的免疫力为宿主克服皮下或呼吸道感染鼠疫提供了主要手段。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号